This Educational Series provides an overview of the data supporting the use of CAR T-cells in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). This is followed by a discussion of the patient's journey, from the initial diagnosis to the challenges of accessing CAR T-cell therapy. Practical recommendations for improving collaboration between community haematologists and designated CAR T-cell Treatment Centres are also included, as is the long-term care of patients within the community post-therapy.
Please login below to download this issue (PDF)